At Nanomics, we believe foundational scientific knowledge​ belongs to the proteomics community. That is why we have filed an invalidation request​ against Seer’s core Chinese patent (ZL202080048647.5) before the CNIPA.

​

The fundamental concepts behind nanoparticle-based enrichment​ have been described in the scientific literature for decades, and workflows using automated sample preparation​ prior to mass spectrometry have been adopted by proteomics researchers for at least ten years.

​

No one should be allowed to patent these long-established principles​ as personal property—or to prevent scientists from freely using them to advance human health. Yet that is precisely what happens when overly broad, generic claims​ are asserted as if they represent novel invention. This is also why, in March 2026, the PTAB​ cancelled central claims​ of Seer’s U.S. patent after finding them unpatentable—confirming these concepts were already part of the prior art.

​

Protecting open science is not antiIP. It is proinnovation.​ Nanomics remains committed to building AI-native proteomics infrastructure by lowering barriers, not fencing off what should remain shared.

​

​

​

About Nanomics

Nanomics is an AI-native company building data infrastructure and foundation models for next-generation precision medicine. Its platform uniquely combines frontier machine learning with scalable proteomics data generation engines—powered by Proteonano and self-driving AutoLab platforms—to lower the barriers to large-scale, biology-native data generation and advance a world model for human biology.

​

​